Loading stock data…
$34.06+7.25 (+27.06%)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Liquidia Corporation in the Healthcare sector is trading at $34.06 with a market capitalization of $6.1B. Wall Street consensus targets $53.50 (8 analysts), implying a +57.1% move over the next 12 months. The stock is currently near its 52-week low of $21.94, remaining 36.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 23 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $171.68M↑ | $132.87M↑ | $92.02M↑ | $54.34M↑ | $8.84M |
| Gross Profit | $160.13M↑ | $121.01M↑ | $84.97M↑ | $51.17M↑ | $7.34M |
| Operating Income | $85.52M↑ | $61.50M↑ | $19.79M↑ | $1.77M↑ | -$37.51M |
| Net Income | $74.72M↑ | $52.86M↑ | $14.55M↑ | -$3.53M↑ | -$41.58M |
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formu...